VERU INC. Logo

VERU INC.

Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.

VERU | US

Overview

Corporate Details

ISIN(s):
US92536C1036
LEI:
Country:
United States of America
Address:
2916 N. MIAMI AVENUE, 33127 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Veru Inc. is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for cardiometabolic and inflammatory diseases. The company's pipeline is primarily focused on enobosarm, an oral selective androgen receptor modulator (SARM) designed to preserve muscle in patients undergoing weight loss therapy with GLP-1 drugs, thereby promoting higher-quality weight loss. Veru is also advancing sabizabulin, a novel oral anti-inflammatory agent for the treatment of atherosclerotic coronary artery disease. In addition to its cardiometabolic focus, the company has also developed therapies for oncology and viral-induced acute respiratory distress syndrome (ARDS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all VERU INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VERU INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VERU INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America COCP

Talk to a Data Expert

Have a question? We'll get back to you promptly.